CClinicalTrials.gg
CompletedNCT01848418SCISCIFUpdated Mar 27, 2026

Conception of an ICF Core Set for Systemic Sclerosis

An observational study in Systemic Sclerosis, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
113
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to create and validate an ICF core Set for Systemic sclerosis

Read the detailed description

In 2002 was published WHO's International Classification of Functioning, Disability and Health (ICF). ICF defines disability as "the negative aspects of the interaction between an individual (with a health condition) and that individual's contextual factors (personal and environmental factors)". Interactions are specified in five domains, classified from body, individual and societal perspectives by means of two lists: a list of body functions and structure, and a list of domains of activity and participation. Since an individual's functioning and disability occurs in a context, the ICF also includes a list of environmental factors.

ICF core sets, which are short lists of ICF categories relevant for specific conditions, serve as practical tools for clinical practice and allow standardisation of data for health information and research. Core sets have already been developed and validated for several musculoskeletal diseases, such as low back pain, osteoarthritis, or osteoporosis, but not yet for systemic sclerosis.

02

Conditions studied

  • Systemic Sclerosis

Browse trials for

Keywords

  • ICF
  • Core sets
  • Systemic sclerosis
  • Function
  • Evaluation
03

In context

Scleroderma, Systemic

688 studies on the registry are indexed under Scleroderma, Systemic; 223 are open to participants now.

This study's enrollment of 113 is above the median of 100 across 169 observational studies indexed under Scleroderma, Systemic.

Browse Scleroderma, Systemic studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male or female aged 18 and older with a diagnosis of ScS made according to ACR and/or Leroy et Medsger criteria

Inclusion criteria

  • Male or female aged 18 and older
  • Diagnosis of ScS made according to ACR and/or Leroy et Medsger criteria
  • Patient giving his informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Severe chronic disease associated with ScS : stroke, multiple sclerosis, Parkinson's disease,…
  • Cognitive or behavioral disorders making assessment impossible
  • Inability to speak and write French
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
113 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Validation of an ICF core Set for Systemic sclerosis

    Submit the list of items to a cohort of 100 patients and experts.

    Time frame: Between the 13th and 24th month

Secondary outcomes

  1. Translation of concepts identified such as items ICF (linking).

    Translation of extracted data and set up the core set

    Time frame: Between the 10th and 12th month

  2. Creation of a database from a qualitative survey

    This database will be elaborated considering information from a qualitative survey of 100 patients, a consultation with experts and a review of the literature

    Time frame: During the first 9 months

07

Study locations

1 site
  • Cochin Hospital
    Paris, 75014, France
08

References and documents

Publications

  • Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustun B, Stucki G. ICF linking rules: an update based on lessons learned. J Rehabil Med. 2005 Jul;37(4):212-8. doi: 10.1080/16501970510040263. PubMed 16024476 ↗
  • Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustun BT, Stucki G. Identification of candidate categories of the International Classification of Functioning Disability and Health (ICF) for a Generic ICF Core Set based on regression modelling. BMC Med Res Methodol. 2006 Jul 27;6:36. doi: 10.1186/1471-2288-6-36. PubMed 16872536 ↗
  • Clements PJ. Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Best Pract Res Clin Rheumatol. 2000 Mar;14(1):1-16. doi: 10.1053/berh.1999.0074. PubMed 10882211 ↗
  • Coenen M, Cieza A, Stamm TA, Amann E, Kollerits B, Stucki G. Validation of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis from the patient perspective using focus groups. Arthritis Res Ther. 2006;8(4):R84. doi: 10.1186/ar1956. PubMed 16684371 ↗
  • Papelard A, Daste C, Alami S, Sanchez K, Roren A, Segretin F, Lefevre-Colau MM, Rannou F, Mouthon L, Poiraudeau S, Nguyen C. Construction of an ICF core set and ICF-based questionnaire assessing activities and participation in patients with systemic sclerosis. Rheumatology (Oxford). 2019 Dec 1;58(12):2260-2272. doi: 10.1093/rheumatology/kez209. PubMed 31219594 ↗
  • Daste C, Abdoul H, Foissac F, Papelard A, Alami S, Kwakkenbos L, Carrier ME, Lefevre-Colau MM, Thombs BD, Poiraudeau S, Rannou F, Mouthon L, Nguyen C. Development of a new patient-reported outcome measure to assess activities and participation in people with systemic sclerosis: the Cochin 17-item Scleroderma Functional scale. Br J Dermatol. 2020 Oct;183(4):710-718. doi: 10.1111/bjd.18922. Epub 2020 Mar 18. PubMed 32017013 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01848418
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
Cabinet d'étude INTERLIS, Ecole des Hautes Etudes en Santé Publique, URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
May 7, 2013
Start date
Oct 27, 2012
Primary completion
Mar 2018
Completion
Mar 2018
Last update
Mar 27, 2026

Study contacts

Agathe Papelard, MD
principal investigator · Cochin Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion